THE OUTBREAK OF COVID-19: A REVOLUTION IN THE REGIME OF I.P. AND COMPETITION LAW

–RanjanKumarRay¹³

-SoumyadeepChakrabarti¹⁴

Abstract

This study’s purpose is to emphasize on how Covid-19 Pandemic affects Competition Law and IPR. As a result of the massive COVID-19 corona virus pandemic, practically all new patent-protected technologies are already in use, from COVID-19 prevention and tracking through vaccinations and medical equipment. Patent rights are morally dubious when they conflict with public health. This paper covers numerous approaches for removing patent thickets. Our results show that patent pledges may help ensure procedural and substantive fairness for the public. The advantages of patent guarantees have led several patent holders to remark on the noble corona virus pandemic publicly.

Keywords IP rights, IPR, Patent pooling, Competition law, COVID-19

On March 11 March 11, 2020, the World Health Organization (hereafter referred as WHO) proclaimed COVID-19 a pandemic caused by the Severe Acute Respiratory Syndrome corona virus (hereafter referred as SARS-CoV-2). There has been a resurgence of interest in the long-standing public policy debate over the nexus between Intellectual Property Right (hereafter referred as IPR), innovation, and public health access to new medicines and technology since the outbreak of SARS. COVID-19 isn’t the first corona virus or pandemic that has ever existed in human history. A “new corona virus” was created in humans by the SARS corona virus. The outbreak started in late 2002 and swiftly grew to 8096 cases and 774 deaths in 30 countries. Despite the lack of a cure, the pandemic finally ended in 2004, with the last case being documented. This year’s pandemic, known as COVID-19, is the first since an influenza pandemic known as swine flu, which infected as many as 1.4 billion people globally in the first year following its breakout between spring 2009 and Spring 2010. Between 151,700 and 575,400 people died, therefore.

13 Assistant Professor of Law at Kalinga University, Raipur, Chhatisgarh, Contact: 8101639574, Email- ranjan.ray@kalingauniversity.ac.in

¹⁴ Assistant Professor of Law at Kalinga University, Raipur, Chhatisgarh, Contact: 9163429861, Email-

soumyadeep.chakrabarti@kalingauniversity.ac.in

Covid-19 and the pharmaceutical industry

An innovator or property developer may earn from their creative effort or reputation via intellectual property rights. Other forms of intellectual property protection are available. Inventions that are innovative, non-obvious and industrially applicable are eligible for patent protection. It is necessary to have IPRs to identify correctly, plan, market, produce, and defend creative work. Every industry must have its IPR regulations, management, strategy, and so on, according to its place of competence. There will be a need for increased emphasis and approach in the pharmaceutical industry’s IPR strategy soon.

The global pharmaceutical industry is driven by scientific knowledge, not industrial know-how, and the Research and Development (hereafter referred as R&D) operations of a corporation are what determines its success. According to some estimates, this has led to a high level of R&D investment in the pharmaceutical industry, which may be as high as 15% of total sales. One of the most challenging tasks in this business is managing innovative risks while still working to gain a competitive advantage over other companies in the field. Research and development in the pharmaceutical industry are fraught with high failure rates. The effect of new medications that do not satisfy stringent safety requirements is often abandoned after an investment of several years’ worth. This will cost you some money. From the moment a chemical is first synthesized until the development of a new medication typically takes eight to ten years. It is becoming increasingly important for pharmaceutical companies to change the focus of their research and development efforts away from creating new technologies for producing existing pharmaceuticals and toward creating innovative pharmacological molecules and chemical entities. In the 1980s, there was a shift in research and development focus away from acute illnesses to long-term chronic ailments. Confirming that one has complied with the standards set forth by many regulatory organizations is essential to penetrating the international market.¹⁵.

More documents must be produced to regulatory authorities in the last decade than combined in the prior ten years. Furthermore, the approval process for new medicines has become substantially more time-consuming. The effort required to bring in a profit is increased to compensate for this shortening of the patent term. Biotechnology-derived drugs, particularly that involving gene usage, may face an even more dire situation. The wealthy nations anticipate pressing for stricter pharmaceutical protections soon enough. It’s also feasible that multiple governments will institute price controls as a means to an end. In the pharmaceutical industry, cutting costs means preparing for reduced profits and spreading out the time it takes to recoup those losses over a more extended period. The pharmaceutical sector, therefore, obviously faces a complex set of rules and regulations. Solutions that both save money and provide advantages in trade have increased in the previous decade to fifteen. Outsourcing research and development, developing partnerships in R&D, and forming strategic alliances are just a few examples.¹⁶

Nature and scope of the pharmaceutical industry

In the race to discover the secrets of the human genome, new scientific knowledge and technological innovations have emerged that are reshaping the pharmaceutical industry’s business model. An advantage for biopharmaceuticals will be that each person’s DNA will be mapped and recorded on an implantable chip, allowing for more customized treatment. Using the data on the chips, doctors can prescribe the proper medication. A primary I.P. concern would be storing individuals’ personal information in such databases. Biotechnologically created medicines will become more widely available. A biotechnologically-created drug will have a different mechanism of protection than a drug that is not biotechnologically created. The patent document must write down microbiological strains before a drug or vaccine can be made. If the pressure has been found before and written about in scientific papers, it is easy to figure out what it is. Under the Budapest Treaty, strains are discovered, developed, and deposited with international depositary authority. These depositories’ databases should also be examined as part of a novelty search. Companies rarely share their work, but it is prudent to wait until a patent application has been filed before exposing an invention in journals or seminars.

A registration number must be cited in the patent specification when dealing with microbiological advances, which necessitates depositing the strain at one of the approved depositories. This removes the necessity for writing down a description of anything alive. Depositing a strain, for example, costs money, although not much if one is not working with cell lines. Furthermore, as in the past, sequences including genes, gene expression, DNA, and RNA must be described in the patent specification. Companies create alliances for several reasons, such as pooling R&D resources and facilities, gaining access to distribution channels, or sharing production resources. Any time you enter an R&D alliance, it’s best to formalize your agreements to address issues like I.P. ownership in several countries, cost- sharing to obtain and maintain I.P. and revenue generated by that I.P. trade secret protection, and dispute resolution. It’s important to remember that an alliance will be more successfulif one of the parties has a more robust I.P. portfolio. This agreement may have additional terms.

Soon, many pharmaceutical companies will contract research with universities, commercial R&D organizations, and government R&D facilities in India and worldwide. Everything described above will be helpful. Keeping studies under wraps will need additional attention.

Intellectual property rights are being overused and abused in the pharmaceutical industry at the expense of consumer welfare and competitiveness. This shows the injustice at the cost of the public benefit when the pharmaceutical sector refuses to take any risks and innovates. Legal reform alone is not enough to correct this injustice. Antitrust law must intervene effectively, even if Congress tries to close loopholes in existing rules and introduce new legislation to limit even more unfair economic practices by the pharmaceutical industry. Antitrust laws have rightly scrutinized mergers and acquisitions and non-competition agreements, but other methods must be addressed. Advocacy and brand name development, as well as granting patents on minor aspects of existing medicines, may help antitrust legislation maintain a healthy balance between rewarding innovation and protecting competition. – Antitrust legislation

Natural botanical-based traditional medicine is integral to human health care in many developing and developed countries, increasing its economic value. The study says more than 60 billion dollarshave been made in sales, with yearly growth rates ranging from 5 to 15%¹⁷. Conventional knowledge-based medicines are often claimed to qualify for patent protection. Researchers or businesses may be able to claim IPR on biological resources and traditional knowledge after a minor change. According to patent filings related to herbal medicine¹⁸ this trend is evident. In the case of patent applications for natural goods, traditional herbal medicine, and herbal medicinal items, each country’s IPR legislation, which is classified into food, pharmaceuticals, and cosmetic categories asappropriate, is followed. The worldwide organized herbal medicine and cosmetic businesses place ahigh value on medicinal plants and related plant goods; therefore, they make excellent candidates forpatent claims.

Patentable Drugs

Writing a patent specification involves combining scientific, technical, and legal skills that take years to perfect. The claims set out in a patent specification form the nucleus of the patent for which a party seeks to assert ownership. No patent may be issued for discovering a unique property in an already- existing chemical compound. An invention may be patented if it can be used in the real world. It is

not patentable to find that an already known substance can withstand mechanical stress, but a railway sleeper constructed from the material may be. Scientists have found a brand-new characteristic even if a sense isn’t brand new. If the combination of well-known substances generates a unique effect, it may be possible to patent it. Insecticides, fertilizers, and medications have never previously been made using this combination. A scientist may have discovered a new molecule, but its structure remains a mystery. The description of the material, its properties, and the process by which it was made will be critical in this case.

Combining well-known substances into valuable products may be patentable if the elements have a functional link when combined. No chemical reaction takes place in this situation at all. A very minimal amount of protection is provided by it. The patent does not cover individual components of the combination. For example, a patent on aqua regia does not preclude someone from mixing the two acids in varying amounts and asking for further patents. “As a result, most countries—except for the United States—do not allow the patenting of human or animal medicinal procedures. Precaution should be exercised while making claims about the unique therapeutic application of a well-known substance. Medications, including herbal ones, account for the vast bulk of the submissions. Among the few applications are engineering, electronics, and chemicals. Approximately 62% of all applications are for drugs and treatments. Patent holders may be able to contribute to the allocation of scarce medical resources by commercializing health-related intellectual technologies. The WHO has licensed multiple COVID-19 vaccinations, and many repurposing drugs have been developed for COVID-19. For developing countries and the poor, patent guarantees from companies like AbbVie and Moderna, Inc. may make it easier for generic drug manufacturers to get free patent licensing, increasing access to medications and vaccinations.

Significance of the Patent Cooperation Treaty

The Patent Cooperation Treaty (hereafter referred as PCT), founded in 1978, is an example of a multilateral agreement to safeguard intellectual property rights. By indicating which countries they are interested in within their PCT application, an inventor from a country that is a contracting state in the PCT can simultaneously gain priority for their innovation within all of the member countries or just one of them. All PCT-related endeavors are coordinated by the World Intellectual Property Organization (hereafter referred as WIPO), which calls Geneva, Switzerland, home. It is necessary to submit a unique patent application for protection in each country of interest. In some instances, this must be done within a predetermined time to maintain priority in these countries. A significant

amount of money would need to be invested in a relatively short time to cover expenses like those associated with filing, translation, and legal representation. Because there is so little time to decide whether or not to apply for a patent in a particular nation, it is also possible that the assumption may not be fully justified. This could be because the decision-making process takes place in that nation.

Inventors from states that are parties to the PCT can get priority for their ideas without having to file separate applications in the countries that interest them. This helps them save money on costs related to translation and other expenses. Under the terms of the new agreement, it provides member countries with significantly more lead time to submit patent applications. Following the Paris Convention, priority in other countries can be obtained after an initial filing has been made for 12 months. The period of protection under the PCT can be between 20 and 31 months. Inventors can benefit from a search report as part of the PCT process to ensure that the claimed invention is novel. Before filing for protection in other countries, the inventor may wish to increase their certainty about the invention’s patentability by requesting a preliminary evaluation to increase the likelihood that the invention will be granted a patent.

Patent pledge: an implications in the context of Covid-19

Making commitments regarding patents is relatively new and is not permitted by either domestic law or international conventions. To foster technological innovation, most nations’ legal systems now include provisions for patenting new inventions and ensuring their protection. The majority of businesses, in the majority of instances, actively pursue high-cost patent licencing alternatives in addition to rigorously enforcing their patent rights. On the other hand, patent pledgors are individuals who have taken the initiative to give up some of their patent rights in exchange for greater access to technology markets. In this case, the patent rights are traded for greater market access. For instance, the Open COVID Pledge and the Open COVID-19 Declaration do not enforce patent rights against anyone who uses the promised patents to defend COVID-19. From a sociological point of view, patent obligations might be able to contribute to an overall improvement in the health and happiness of society. An incentive in the form of a patent pledge is offered to patent holders in the hope that they will agree to move away from the conventional licencing model and toward the open approach. Most parties involved in patent litigation do not attempt to have long-term patent infringements halted by either a temporary or permanent injunction. Some patent holders have committed that they will not go after patent royalties for a set period. This is only a possibility if the other party satisfies a set of conditions that have been established.

People who take the Open COVID Pledge or participate in Open COVID-19 agree not to seek monetary compensation or use patent rights. Intellectual property owners make significant economic decisions when they give up certain rights. This decision may benefit society as a whole and does not harm any organizations or individuals. The holders of patents will experience short-term losses as a direct consequence of the guarantee of patent rights. In the long run, a patent holder may acquire competitive advantages and opportunities for partnership if they implement a long-term development strategy or make an effort to improve public health.¹⁹.

Patent pledges cannot safeguard all members’ common interests because of their many complex patent promises. It’s not uncommon to see a patent promise with conditions attached, such as a restriction on the technology, a location, or expiration date. As a result, the vast majority of patent promises will be able to be used under the connected requirement rather than under all circumstances. Making a patent promise as part of an open patent strategy can help companies address the conflict between exclusive patent rights and the interests of society as a whole. Following an available patent strategy, companies may promise to distribute their patent licences. Procedural fairness considerations favour patentees, not third parties, in the patent commitment process.

Since Open COVID Pledge has made the standard requirements available on its official website, it may encourage more small and medium-sized businesses to sign patent pledges opposing Open COVID-19. As soon as they’ve submitted commitments, patent holders are expected to keep their promises not to sue or seek compensation for anything, including using their patent rights to stop the spread of COVID-19. As a result of patent promises, a community’s common good and social well- being are protected since patent holders give up part of their related patent rights.

Importance of a patent pledge

Several methods may be used to clear patent thickets. Efficiency studies show that patent holders that join to assert their rights during the COVID-19 outbreak will do better than their pledgors who opt out. To resist COVID-19, many patent holders made pledges rather than instituting compulsory licensing or joining patent pools. As part of our investigation of the advantages of patent promises, we evaluate three methods for avoiding patent disputes from an ethical perspective.

TRIPS establish minimum requirements for the protection of intellectual property for the 164 members of the World Trade Organization (WTO). Member states’ licencing policies should adhere to Article 31²⁰, although they differ from one another. Thus, Article 31²¹ is used as a case study to analyze compelled licensing from both an efficiency and corporate ethical perspective. Patent promises are beneficial in the fight against the COVID-19 epidemic.

Making a patent promise is simpler and more manageable from a procedural fairness aspect than creating a patent pool or issuing a compelled licence. To understand compulsory licensing, one must consider it a specific claim that a government must grant. In contrast, patent pooling may be seen as a collective activity in which numerous patent owners are willing to enter into licence agreements. Compulsory licensing or organizing a patent pool is a long and tedious procedure. On the other hand, patent promises are specific pledges or commitments to provide patent licences. Due to standardized patent pledges like Open COVID Pledge-Patent, patent holders have an easier time fulfilling their agreements to provide patent rights. A growing number of small and medium-sized enterprises are making patent commitments to fight COVID-19 because of the simplicity of the process.

Second, patent pledges will allow patent holders to give up some of their rights, which will help the general public achieve the highest possible level of substantive justice. Two types of patent promises can be made regarding COVID-19: unilateral and coordinated. Unilateral patent promises with specific conditions offer various options, including free licences or non-discriminatory royalty rates. There must be no injunction against patented technology users, regardless of the kind of patent promise made by the patent owners. The ability of patent holders to get international licensing may be enhanced by the fact that patent obligations may cross national borders. Due to patent commitments, generic drugmakers are compelled to manufacture COVID-19 drugs or vaccines under an open licence. Increasing the availability of medicines and vaccines in the case of the COVID-19 pandemic will significantly boost access to life-saving therapies. As patent holders give up more rights, the public gains more from their obligations.

It can decrease the conflict between public health and intellectual rights by balancing patent promises’ short-term costs and benefits. The COVID-19 pandemic necessitated the voluntary surrender of patent holders of some rights. For a specific time, patent holders give up their secured patent rights. However, patent rights will be restored after the COVID-19 outbreak is over. In the long run, patent holders will develop a reputation for social responsibility and have more possibilities for licencing their patent despite the short-term loss of money.²²

Advantages of patent pledge

A long-term strategy of free patent licencing will harm businesses’ long-term growth. Protecting patent rights is essential for the medical industry to innovate and flourish. Making new medicines and vaccines costs a lot of time, money, and effort, but there are also a lot of risks involved. Patent protection may help the pharmaceutical industry’s bottom line by preventing innovations from being copied.

A fair global distribution of medical resources for COVID-19 can’t be achieved just by relying on patent obligations. Because of patent promises, the supply of medications and vaccines will not be significantly enhanced if no generic manufacturers create pharmaceuticals or vaccinations for COVID-19. Since they connect research and development to products, patents are frequently seen as significant outputs of innovation activities and crucial technological resources for new product creation.²³.

Disadvantages of patent pledges

Patent promises may be unsustainable for an extended period of no accompanying supportive measures exist. As a consequence of our findings, policymakers and business leaders will be better equipped to address public health crises using patent portfolios.

The Open COVID Pledge and Open COVID-19 have been formed to counteract COVID-19, which has increased in firms signing patent agreements. The paper examines the advantages and cons of patent agreements using an analytical methodology that incorporates efficiency and corporate ethics. The management must deal with the ramifications of our findings.

Patent holders should be encouraged to make active pledges in their fight against COVID-19, either by the WHO or the WIPO. For access to patented health innovations, patent holders agree to give up some of their rights, such as the right to seek injunctive relief against patent users. As of April 2021, SAGE recommends several vaccines for COVID-19, with 88 currently in clinical trials and 184 in the pre-clinical stages. Patent pledges for COVID-19 have been made by just a few companies, including Moderna, which has a patent for its mRNA-1273 vaccine. More pharmaceutical and vaccine patent holders should sign on to the WHO’s suggested patent pools, C-TAC or MPP so that the pools may be formed as quickly as possible.

National governments should be more involved in developing and distributing COVID-19 treatments and vaccines—unaffordable assurances of free patent protection for companies who have invested

Significantly in developing new medical technologies. The government of a country is obligated by law to provide for the people’s people’s medical needs. To address the disadvantages of patent promises, national governments should give various legislative mechanisms to boost COVID-19 health technology. There are several ways in which public monies may be used to support the development of health technology, such as by providing funding to national firms or by purchasing healthcare services for the general population. Consequently, patent holders can meet their promises in the face of government support.

Third, in the wake of the global COVID-19 outbreak, corporations should consider making a patent guarantee, whether unilaterally or in concert with other companies. There can be little doubt that patent entanglement will hinder the use of valuable medications to improve public health. To get through the patent maze created by the COVID-19 epidemic using traditional methods such as voluntary licensing or patent pools is nearly impossible. COVID-19 manufacturers can use proprietary health technologies because of patent agreements. Life-saving healthcare may become more accessible as diagnostics, treatments, and vaccines become more widely available. TheCOVID- 19 pandemic will be contained and finally extinguished if international organizations and national governments, patent holders, and manufacturers work together.

Managing I.P. and IPR is a complicated process that includes several activities and procedures that must comply with national and international treaties and conventions. It’s no longer solely a matter of national interest anymore. I.P. and its associated rights are heavily influenced by various factors, including consumer demand, market response, and the financial burden of commercializing an invention. So, in other words, trade and commerce are critical in the administration of IPRs. Many kinds of IPR need various approaches to managing, planning for, and preparing for, as well as the engagement of personnel with a wide range of subject-matter expertise. There should be different

I.P. regulations, management styles, and strategies for each industry based on its area of competence. The pharmaceutical industry is implementing a new I.P. strategy. Because of the increasing chance that particular IPRs are invalid, antitrust law must intervene to ensure that illegitimate, though limited, monopolies in the pharmaceutical industry are not built and maintained unlawfully. There is still a slew of concerns to be resolved in this context.²⁴.

4.3. Waiver of I.P.: amidst Covid-19

With the wealthiest countries currently holding a large portion of the global supply of covid-19 vaccines, intellectual property rights must be waived to alleviate this inequality. As of April 30 April

30, 1.3 billion doses have been delivered worldwide, but just 0.2 per cent of those doses to low- income countries. I.P. waivers have the unfortunate effect of allowing competitors to get expensive innovations more quickly. Because vaccine components are rare and it may take years to build up manufacturing capacity from the ground up, companies argue that I.P. relief would not speed up vaccine production.

Other nations argue that governments can already seek ‘compulsory licensing’ to bypass intellectual property laws in times of crisis. The World Trade Organization is now reviewing Bolivia’s request to import COVID vaccines in this method. Additionally, the European Union claims that the United States is obstructing the shipping of COVID-19 vaccinations and the components that go with them. Bringing this up is appropriate. Pandemic restrictions would need to be eased in the case of an outbreak.

They think these are critical problems that need to be dealt with. There are not, however, sufficient reasons to deny I.P. relief. Even as the pandemic worsens, the case for waiving the ban becomes stronger.

Because vaccine manufacturing, research and development are concentrated in a small number of high- and middle-income countries, there is a severe problem. The great majority of vaccine doses have been sold to governments in high-income nations by companies based in these countries, who also hold the majority of the intellectual property. Out of the 8.6 billion confirmed orders, 6 billion doses have been pre-ordered by governments in high- and middle-income countries.

European nations committed at the Global Health Summit in Rome last week, just before the World Health Assembly in Geneva, Switzerland, to share extra vaccine doses with low- and middle-income countries. European Commission President Ursula von der Leyen has also advocated ‘clarifying and simplifying the present means for imposing mandatory licensing. ‘ There is a fair chance that more vaccine funding will be offered during the G7 meeting in the United Kingdom next month.

Pledges like this are vital if we want to stop the spread of the disease. They do not, however, address the fundamental issue – the countries who support the I.P. waiver are not seeking charity but rather the ability to study and produce their vaccines without fear of being sued by patent holders. COVID’s

I.P. waiver supporters are aware of this basic notion. Those countries’ leaders who are still opposed to allowing patents to be waived need to realize this as well. Pharma companies and most nations with high affluence were opposed to the concept at the time. As an alternative, these nations have agreed to boost funding for programmes like COVAX, which provides vaccines to low-income countries. Last month, the United States only recently backed a vaccine I.P. waiver, which was an unexpected and much-needed step forward.

Considering the size of the U.S. pharmaceutical business alone, this choice is of critical significance.

I.P. norms have been established and enforced by the United States and other research-intensive nations for decades, most recently via the WTO, where a proposed I.P. waiver is now under discussion. Even a few months ago, the idea that the United States would take such a position was unthinkable. After Japan, South Korea, the United Kingdom, and the European Union have done so, the rest of the world must follow suit.²⁵.

Global approach for the waiver of I.P.

Covid-19 containment and treatment under the TRIPS Agreement were suggested to the World Trade Organization on October 2, 2020, by both India and South Africa. This initiative aims to reduce obstacles to timely access to inexpensive, appropriate medical items and encourage global immunizations. For the worldwide reaction to be effective, these products must be quickly accessible, and the whole world must cooperate in this effort. According to the Max Planck Institute for Innovation and Competition’s recently issued position statement, such a waiver is unlikely to be needed or suitable to achieve the stated goals. The following are some of the study’s most significant findings.²⁶:-

• A scarcity of raw ingredients, limited production capacity, and, in the case of vector and mRNA vaccines, very sophisticated manufacturing procedures is the principal causes of vaccine A surrender of intellectual property rights cannot solve these difficulties.
• It takes a long time to create a new vaccine because of the many steps involved, starting with the provision of a technological basis and continuing through safety studies and eventual However, despite the usual fierce competition in the biopharmaceutical industry, vaccines against Covid-19 are being developed, manufactured, and marketed in unprecedented cooperation.
• Patents are often utilized as a basis for this kind of partnership since they guarantee the performance of Even a fair abridgement of these rights may have a chilling effect on a party’s motivation to work together.

The applicable drug authorities need marketing authorization to put a medical product on the market. Even bio-similars, copies of small-molecule drugs but subject to far tighter regulations than generics,

fall under this category. The third party does not need marketing permission if the original manufacturer successfully transferred the licence. Even if all applicable intellectual property rights, including the exclusivity of test results, were waived, each new producer would still be required to get its marketing licence and fulfil safety, quality, and efficacy criteria. If the original manufacturers refuse to cooperate, the transfer of intellectual property rights will inevitably cause a delay.

However, there are several reasons why biosimilars costs would not be considerably lower than those of current goods, such as the following:

• Production facilities, especially new vaccines, need large expenditures, which are unlikely to be lower for bio-similar and show in their price.
• Because the manufacturing and distribution expenditures may be as much as half of the vaccine’s price, bio-similar vaccines are unlikely to cut the vaccine’s cost significantly.
• Because of the increased competition, vaccination prices and profit margins will become more
• Vaccines are already available at a reasonable cost from certain vaccine producers and

Article 31 of the Agreement²⁷ authorizes WTO members to grant patents compulsory licences under specific situations. If patentees refuse to provide production licences for unjustified reasons, member states can incorporate this option into their national law. International law’s ability to adapt to the present-day unprecedented conditions is not hampered by the measures taken by particular states, as shown by the information available.

As Covid-19 viruses evolve, we may need new vaccinations to protect against them. Because of this, it is uncertain whether vaccine developers would be willing to invest in new vaccines without patent protection. Patents in other medical fields, such as cancer therapy, also cover Covid-19 vaccines already licensed. To produce the vaccine, fundamental patents would have to be relinquished. Aside from immunizations, this might have unforeseen repercussions in terms of financial incentives for future research and development.

Companies must be able to make a decent return from their R&D investments to motivate them to engage in R&D. The fundamental question is how much justification there is for a specific expenditure. A patent right may not necessarily result in high prices for Covid-19 vaccines, primarily when multiple vaccines compete. Governments supporting vaccine manufacturing should have handled pricing difficulties via equivalent agreements and created legally enforceable standards.

There must be transparency on the overall investment and the calculation associated with the sale of the resulting medicines and vaccines if taxpayer money is being utilized for pharmaceutical research and development or manufacturing facilities. It is the role of the funding agency to make sure that recipients of its money reveal their costs and pricing structures since private enterprises cannot be expected to do so.

However, any intellectual property rights based on Covid-19 would be relinquished as a part of the proposed TRIPS Agreement renunciation. However, the phrase ‘concerning might be interpreted in various ways. Because of the idea that governmental action must be necessary and acceptable, this is problematic. As a result, the extent to which we may waive intellectual property rights for things just accidentally linked to immunizations would be significantly altered.

Promoting equitable access to vaccinations and medications associated with Covid-19 is an issue of international solidarity. The international community must find alternative methods since waiver of intellectual property rights cannot be used to attain this goal. Good governance requires an adequate international legal framework to deal with such global issues in the future. More than 25 countries and organizations, including Germany, have requested a worldwide pandemic treaty. ACT-A and COVAX programmes and other international strategies are being used to control the outbreak in certain areas. Every state that can contribute has to do so. National interests alone and pushing for intellectual property rights waivers will not increase immunization availability in developing countries in the foreseeable future.

Conclusion and Recommendation

Patent protection is advantageous to pharmaceutical companies. When the patent on the original product expires, generic versions of the same product will be available on the market. Competition rules in the European Union may prohibit pharmaceutical companies from attempting to prolong a product’s patent protection. As generic items foster the invention of new products, such conduct may have the unintended effect of eliminating incentives to innovate. Furthermore, Astra-Zeneca was discovered to be abusing the patent system, and medical approval process, so generic and parallel imported drugs could not compete with its blockbuster drug. A 60 million euro fine was levied on Astra-Zeneca. Currently, the appeal is being heard by the Court of First Instance. As a result of this first incident, the Commission has intensified its monitoring of competition in the generic pharmaceutical market. Competitor in the human pharmaceutical industry seems to be lacking in Europe, with fewer new medications entering the market and the introduction of generic drugs being delayed from time to time, according to early results. Consequently, the Commission has begun an

inquiry into why this happened.

There is no plan in place in India to allow the I.P. and competition laws to function in harmony at this time. The Indian government and the competition commission of India (hereafter referred as CCI) are unsure how to handle the thorny issue of competition law that intersects with the rights to intellectual property. By allowing Patent Holders to operate freely and within the bounds of competition law without CCI intervention, essential practice theory would enable Patent Holders to thwart patent pooling, which has a detrimental effect on competition and innovation. The I.P. and competition regimes share the primary purpose of benefiting the economy, which is vital to ensure this convergence.

A detailed examination of the Competition Act suggests that the Competition Commission is competent to consult with other sectoral regulators. Still, because the rules are neither mandatory nor binding, this is only partially addressed and executed. The TRIPS also urges countries to improve their I.P. protection systems. As a result, international engagements, as well as international legislation, must be considered. The E.U. and the U.S. have taken a balanced approach in this regard. They believe the abuse of a monopoly market structure by the owner of an intellectual property right to be the exception rather than the rule. Because Indian belief draws mainly on common law, especially in economic direction, both the E.U. and U.S. methods can help policymakers reach a reasoned conclusion or build a flexible policy where I.P. rights and competition law intersect.

The CCI has classified Patent Pooling agreements as restrictive trade practices since they impede India’s competitive regime. However, Section 102 of the Indian Patent Act allows for establishing patent pooling agreements that can be administered, maintained, and monitored by the government. The primary concern is whether India’s competition law can regulate such deals amidst Covid-19 chaos.

The Indian government requests an intellectual property rights waiver under the Agreement on Trade-Associated Aspects of Intellectual Property Rights. The assumption behind seeking an IPR waiver is that it will allow more companies to manufacture vaccines and medications, increasing their availability at a lower cost. IPR exemptions for COVID-19 vaccines and pharmaceuticals, on the other hand, are unlikely to make a difference. A more successful strategy is using compulsory licences and lowering tariffs and non-tariff measures.